MAPT and Alzheimer disease: Compared to currently approved treatments for AD, anti-tau monoclonal antibodies offer several advantages: (1) Targeted pathological mechanism: Unlike AChEI and NMDA-RI, anti-tau monoclonal antibodies directly target tau proteins, aiming to fundamentally alter disease progression rather than merely alleviating symptoms (Li et al., 2022; Shukla et al., 2022).